

ONPATTRO[®]

(patisiran)

Dosing and Preparation Guide



Indication

ONPATTRO[®] (patisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. Monitor for signs and symptoms during infusion. Slow or interrupt the infusion if clinically indicated. Discontinue the infusion if a serious or life-threatening infusion-related reaction occurs.

Please see Important Safety Information on [page 16](#)
and full [Prescribing Information](#).

onpattro[®]
(patisiran) lipid complex injection
10 mg/5 mL

hATTR amyloidosis: a multisystem disease with frequent and early polyneuropathy manifestations¹⁻⁵

Hereditary transthyretin-mediated (hATTR) amyloidosis is caused by a variant in the transthyretin (TTR) gene that results in the accumulation of amyloid deposits in multiple organs of the body.^{3,6,7}

Early symptoms of hATTR amyloidosis may include³:



Peripheral sensory-motor neuropathy

(e.g., neuropathic pain, paresthesia, weakness, bilateral carpal tunnel syndrome, difficulty walking)



Autonomic neuropathy

(e.g., orthostatic hypotension, recurrent urinary tract infections, sexual dysfunction, sweating abnormalities, urinary retention)



Gastrointestinal manifestations

(e.g., diarrhea, nausea, vomiting, unintentional weight loss)

hATTR amyloidosis has a heterogeneous symptom presentation. Other symptoms that may raise clinical suspicion include^{3,8}:

- **Cardiovascular manifestations**
(e.g., arrhythmias, conduction abnormalities, heart failure)
- **Renal abnormalities**
(e.g., renal impairment, cardiorenal syndrome)
- **Ocular involvement**
(e.g., vitreous opacity, glaucoma)

ONPATTRO® (patisiran) does not treat all of the symptoms of hATTR amyloidosis.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

ONPATTRO® (patisiran)—the first FDA-approved RNAi therapeutic

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

- ONPATTRO is a double-stranded small interfering ribonucleic acid (siRNA) formulated as lipid nanoparticles for targeted delivery to hepatocytes, the primary source of TTR protein production^{9,10}
- ONPATTRO is administered via intravenous (IV) infusion once every 3 weeks. For patients weighing <100 kg, the recommended dose is 0.3 mg/kg. For patients weighing ≥100 kg, the recommended dose is 30 mg⁹
- ONPATTRO is supplied as a 10 mg/5 mL solution in a single-dose glass vial⁹

ONPATTRO is a white to off-white, opalescent, homogeneous solution.⁹ Note that there may be a white coating visible on the inner surface of the vial. This is normal and does not impact the product quality.



APOLLO study: ONPATTRO demonstrated a significant improvement versus placebo across multiple endpoints at 18 months⁹

- ONPATTRO-treated patients had an 84% mean reduction of serum TTR at 18 months^{9,11}
- For the primary endpoint, mNIS+7, LS mean change from baseline was -6.0 points (improvement) for ONPATTRO-treated patients versus 28.0 points (worsening) for patients who received placebo, a difference of -34.0 points^{9,12}
 - mNIS+7, an objective 304-point scale, assessed motor strength, reflexes, sensation, nerve conduction, and postural blood pressure
- For the key secondary endpoint, Norfolk QoL-DN, LS mean change from baseline was -6.7 points (improvement) with ONPATTRO compared with 14.4 points (worsening) with placebo, a difference of -21.1 points^{9,13}
 - Norfolk QoL-DN score is a patient-reported assessment that evaluated neuropathy in domains such as physical functioning, activities of daily living, symptoms, and autonomic neuropathy (score ranges from -4 to 136)

LS=least squares; mNIS+7=modified Neuropathy Impairment Score + 7; Norfolk QoL-DN=Norfolk Quality of Life-Diabetic Neuropathy; RNA=ribonucleic acid; RNAi=RNA interference.

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

Preparation and dosing

To prepare ONPATTRO® (patisiran), you will need:

- ✓ DEHP-free infusion bag containing 0.9% Sodium Chloride Injection, USP (normal saline solution). Total volume needed: 200 mL
Important: If using a 250 mL infusion bag, it is necessary to remove the calculated volume of ONPATTRO plus 50 mL of normal saline to ensure that the total final volume is 200 mL
- ✓ 0.45 micron PES syringe filter
- ✓ Empty sterile container (e.g., a glass vial or an empty syringe)
- ✓ Syringes, needles, and standard IV preparation materials
- ✓ DEHP-free extension set with 1.2 micron PES in-line infusion filter (for administration of the infusion)

Dosing⁹

ONPATTRO is supplied as a 10 mg/5 mL solution in a single-dose glass vial.

ONPATTRO is administered via an ~80-minute IV infusion once every 3 weeks.

Dosing is based on actual body weight. For patients weighing <100 kg, the recommended dose is 0.3 mg/kg. For patients weighing ≥100 kg, the recommended dose is 30 mg.

Use the dosing guide on [page 18](#)
for quick, easy dosing calculations.

DEHP=di(2-ethylhexyl)phthalate; PES=polyethersulfone.

Please see **Important Safety Information** on [page 16](#)
and full [Prescribing Information](#).

Premedication⁹

All patients should receive premedication prior to ONPATTRO® (patisiran) administration to reduce the risk of infusion-related reactions (IRRs).

Each of the following premedications should be given on the day of the infusion **at least 60 minutes prior to the start of infusion**:

- IV corticosteroid (e.g., dexamethasone 10 mg, or equivalent)
- Oral acetaminophen (500 mg)
- IV H1 blocker (e.g., diphenhydramine 50 mg, or equivalent)
- IV H2 blocker (e.g., famotidine 20 mg, or equivalent)

For premedications not available or not tolerated intravenously, equivalents may be administered orally.

For patients who are tolerating their ONPATTRO infusions but experiencing adverse reactions due to the corticosteroid premedication, the corticosteroid dose may be reduced by 2.5 mg increments to a minimum dose of 5 mg of dexamethasone (IV), or equivalent.

Some patients may require additional or higher doses of 1 or more of the premedications to reduce the risk of IRRs.

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).



Preparation and handling⁹

ONPATTRO® (patisiran) must be filtered and diluted prior to IV infusion. The diluted solution for infusion should be prepared by a healthcare professional using aseptic technique as follows:

1. Remove ONPATTRO from the refrigerator and allow to warm to room temperature. Do not shake or vortex.
2. Inspect visually for particulate matter and discoloration. If the vials are discolored or foreign particles are present, do not use the vials and report the issue to Alnylam at 1-877-ALNYLAM.

Note: ONPATTRO is a white to off-white, opalescent, homogeneous solution. A white coating may be observed on the inner surface of the vial, typically at the meniscus. This does not impact the quality of the drug. The coating may remain in the vial after withdrawing the solution. This also does not impact product quality.


3. Calculate the required dose of ONPATTRO based on the recommended weight-based dosage. **Please see the dosing guide on [page 18](#).**
4. The final total volume of the ONPATTRO infusion should be 200 mL. From the DEHP-free infusion bag containing 0.9% Sodium Chloride Injection, USP, remove the calculated volume of drug plus any extra saline.
 - If using a 250 mL infusion bag, it is necessary to remove the calculated volume of ONPATTRO plus 50 mL of normal saline
5. Withdraw the entire contents of all of the vials needed into a single sterile syringe.




Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

Preparation and handling (cont'd)⁹

6. Filter ONPATTRO® (patisiran) through a sterile 0.45 micron PES syringe filter into a sterile container such as a sterile glass vial or sterile syringe. **Do not filter the drug out of the vial directly into an IV bag.**




7. If using a sterile glass vial, withdraw the calculated dose of filtered ONPATTRO from the sterile container using a new sterile syringe.



If filtering into a second sterile syringe, ensure that the full calculated dose of ONPATTRO has been filtered into the container.


8. Dilute the required volume of filtered ONPATTRO into a 200 mL DEHP-free infusion bag containing 0.9% Sodium Chloride Injection, USP.



9. Gently invert the infusion bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.

- ONPATTRO should not be delivered via pneumatic tube systems

10. Discard any unused portion of ONPATTRO.



Important Safety Information

Adverse Reactions


The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

Administration⁹

The steps below provide the instruction you'll need to administer ONPATTRO[®] (patisiran):

1. Use a dedicated line with an infusion set containing a 1.2 micron PES in-line infusion filter. Use infusion sets and lines that are DEHP-free.
2. Infuse the diluted solution of ONPATTRO intravenously, via an ambulatory infusion pump, over approximately 80 minutes at an initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion.



The duration of infusion may be extended in the event of an IRR. See [page 10](#) for details about what to do in the case of IRRs.

3. Administer only through a free-flowing venous access line. Monitor the infusion site for possible infiltration during drug administration. Suspected extravasation should be managed according to local standard practice for nonvesicants (pH of ONPATTRO solution is ~7.0).
4. After completion of the infusion, flush the IV administration set with 0.9% Sodium Chloride Injection, USP, to ensure that all ONPATTRO has been administered.

Observe the patient during the infusion and, if clinically indicated, following the infusion.

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

Administration (cont'd)⁹

Considerations when preparing the dose

Proper preparation of ONPATTRO[®] (patisiran) requires filtration to remove particulates. An additional vial of ONPATTRO may be required depending on the type of filter used and the amount of product that remains in the filter (hold-up volume).⁹ **The dosing guide found on [page 18](#) assumes that 1 mL of drug product remains in the filter when determining the number of vials needed**, based on the manufacturer's information for the Pall PharmAssure[®] 0.45 micron 32 mm syringe filter with low protein binding Supor[®] membrane (Product ID HP4644).¹⁴

The diluted solution should be administered immediately after preparation.

- If not used immediately, store in the infusion bag at room temperature (up to 30°C [86°F]) for up to 16 hours (including infusion time)
- Do not freeze

Missed dose⁹

If a dose is missed, administer ONPATTRO as soon as possible.

- If ONPATTRO is administered within 3 days of the missed dose, continue dosing according to the patient's original schedule
- If ONPATTRO is administered more than 3 days after the missed dose, continue dosing every 3 weeks thereafter

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

Infusion-related reactions⁹

IRRs have been observed in patients treated with ONPATTRO[®] (patisiran).

In clinical studies, all patients received premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) to reduce the risk of IRRs. In a double-blind, placebo-controlled study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients.

- Among ONPATTRO-treated patients who experienced an IRR, 79% experienced the first IRR within the first 2 infusions. The frequency of IRRs decreased over time
- Across clinical studies, the most common symptoms (reported in $\geq 2\%$ of patients) of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache
- Severe hypotension and syncope have been reported as symptoms of IRRs in the expanded access program and postmarketing setting
- IRRs resulted in permanent discontinuation of ONPATTRO in $< 1\%$ of patients in clinical studies

Management of IRRs

- If an IRR occurs, consider slowing or interrupting the ONPATTRO infusion and instituting medical management (e.g., corticosteroids or other symptomatic treatment) as clinically indicated



If a patient has a mild to moderate IRR that requires interruption of the infusion, consider resuming the infusion at a slower rate only if symptoms have resolved.

- In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed

Some patients who experience IRRs may benefit from a slower infusion rate or additional or higher doses of 1 or more of the premedications with subsequent infusions to reduce the risk of IRRs.

To report suspected adverse reactions, contact Alnylam Pharmaceuticals at 1-877-ALNYLAM (1-877-256-9526), or the FDA at 1-800-FDA-1088, or go to www.fda.gov/medwatch.

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

Storage and handling⁹

- Store ONPATTRO[®] (patisiran) vials at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard vial if it has been frozen
- If refrigeration is not available, ONPATTRO vials can be stored at room temperature up to 25°C (up to 77°F) for up to 14 days

After preparation:

ONPATTRO does not contain preservatives. The diluted solution should be administered immediately after preparation. If not used immediately, store in the infusion bag at room temperature (up to 30°C [86°F]) for up to 16 hours (including infusion time). Do not freeze.

Consider home administration



Home administration may be an option for some patients. The decision for a patient to receive home administrations should be made after an evaluation and recommendation by the treating physician, and may not be covered by all insurance plans. Some physicians may choose to have patients receive their first few infusions in the clinic prior to transitioning to home administration. Regardless of the setting, ONPATTRO infusions should be performed by a healthcare professional.

Alylam Assist[®] can help answer questions about home administration.

Ongoing support from Alylam Assist

Alylam Assist offers a wide range of services to guide your patients through treatment with ONPATTRO, including:

- Disease education and support for your patients that is customized to their communication preferences
- Comprehensive reimbursement education and patient-specific benefit verification
- Ordering assistance and facilitation of delivery via specialty distributor or specialty pharmacy



8AM–6PM, Monday–Friday

📞: 1-833-256-2748 | 🖨️: 1-833-256-2747

To learn more visit www.AlylamAssist.com.

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

Dosing and preparation FAQs

1. Are substitutions permitted for the IV premedications? Can they be given orally?

IV equivalents of dexamethasone, diphenhydramine, and famotidine may be used per the judgment of the prescribing physician. For premedications not available or not tolerated intravenously, equivalents may be administered orally.

2. What is the white coating in the ONPATTRO® (patisiran) vial?

ONPATTRO is a white to off-white, opalescent, homogeneous solution. Some of the product residue may be observed on the inner surface of the vial, typically at the meniscus. This coating may remain in the vial after withdrawing the solution and does not impact the quality of the drug.

3. How many vials of ONPATTRO are needed to prepare my patient's dose?^{9,14}

ONPATTRO is administered via IV infusion once every 3 weeks. Dosing is based on actual body weight. For patients weighing <100 kg, the recommended dose is 0.3 mg/kg. For patients weighing ≥100 kg, the recommended dose is 30 mg. ONPATTRO is supplied as a 10 mg/5 mL (2 mg/mL) solution in a single-dose vial. Proper preparation requires filtration to remove particulates. An additional vial of ONPATTRO may be required to prepare the full recommended dose, depending on the type of filter used and the amount of product that remains in the filter (hold-up volume). The dosing guide on [page 18](#) assumes that 1 mL of drug product remains in the filter when determining the number of vials needed. Consult the dispensing pharmacy or filter manufacturer to determine the expected hold-up volume for the filter used to prepare the ONPATTRO dose.

4. What size IV bag is needed to prepare ONPATTRO?

The final total volume of the prepared ONPATTRO dose is 200 mL. If using a 250 mL infusion bag, it is necessary to remove the calculated dose of ONPATTRO plus 50 mL of normal saline to ensure that the total final volume is 200 mL.

5. Can I filter ONPATTRO directly out of the vial and into the infusion bag?

ONPATTRO must be filtered through a 0.45 micron PES syringe filter into a sterile container, prior to diluting it into the infusion bag using a sterile syringe. Filtering ONPATTRO directly out of the vial would cause shearing of the lipid nanoparticles due to increased pressure, preventing the active drug from being delivered to the hepatocytes, and therefore is not recommended.

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

6. What should I use for a sterile container during step 6, on page 7?

Options for sterile containers include glass containers, vials, or sterile syringes.

7. Can a different size PES filter be used during step 6, on page 7?

If 0.45 micron PES filters are unavailable, 0.2 micron PES filters can be used; however, each vial of ONPATTRO® (patisiran) will require filtration through a separate 0.2 micron filter due to the smaller pore size.

8. Why does ONPATTRO preparation require 2 filtration steps?

The protocol for preparation of ONPATTRO includes filtering the drug through a 0.45 micron PES filter prior to diluting in an infusion bag of normal saline. The prepared drug is then infused from the bag through a second 1.2 micron PES in-line filter. The use of 2 filtration steps ensures delivery of ONPATTRO without residual particles that could cause filter-clogging events during the infusion.

9. What should be done if my patient experiences an infusion-related reaction (IRR) during the ONPATTRO infusion?

If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management if clinically indicated. If the infusion is interrupted, consider resuming at a slower rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

For additional questions regarding ONPATTRO, please contact Alnylam Medical Information at 1-877-ALNYLAM (1-877-256-9526) or medinfo@alnylam.com.

Please see Important Safety Information on [page 16](#)
and full [Prescribing Information](#).

Ordering filters through McKesson^a

Options for ordering the filters needed to prepare and administer ONPATTRO[®] (patisiran) through McKesson Plasma & Biologics or McKesson Specialty Health

McKesson Plasma & Biologics



Online: connect.mckesson.com



Email: mpborders@mckesson.com



Phone: 1-877-625-2566



Fax: 1-888-752-7626

McKesson Specialty Health



Online: mscs.mckesson.com



Email: mshcustomercare-mspl@mckesson.com



Phone: 1-855-477-9800



Fax: 1-800-800-5673

Filters available for order^b

Filter Name	Quantity	Manufacturer Product #	McKesson Plasma & Biologics Product #	McKesson Specialty Health Product #
EMD Millipore Millex-HP Syringe Filter Unit, 0.45 µm, PES, 33 mm	50	SLHP033RS	3955036	5503021
	250	SLHP033RB	3955028	
B Braun Medical, Inc. Extension Set, 1.2 Micron Filter, Luer Lock Connector, DEHP-Free, 4.3 mL Priming Volume, 10" L, Latex Free	50	473994	3954971	5502260

^aCost of filters ordered through McKesson is the responsibility of the healthcare professional and is not covered by Alnylam.

^bThe list of filter options above is not comprehensive. Alnylam does not endorse or recommend any specific filter manufacturer for the preparation and administration of ONPATTRO.

If you do not have a McKesson account, get started by calling 1-877-625-2566 to speak with a McKesson Service Representative.

Note: Both a 0.45 micron PES syringe filter and a 1.2 micron PES in-line infusion filter are needed to prepare and administer ONPATTRO.

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).


Ordering filters through a specialty pharmacy


Options for ordering the filters needed to prepare and administer ONPATTRO® (patisiran) through Orsini Healthcare or CVS Specialty Pharmacy

For sites purchasing ONPATTRO through one of the following specialty pharmacies, filters may be available for order.

Orsini Specialty Pharmacy


1111 Nicholas Boulevard
Elk Grove Village, IL 60007


 **Phone:** 1-800-690-8236

 **Fax:** 1-877-445-8481

CVS Specialty Pharmacy

800 Biermann Court, Suite B
Mount Prospect, IL 60056

 **Phone:** 1-866-526-4984

 **Fax:** 1-855-592-6890



8AM–6PM, Monday–Friday

: 1-833-256-2748 | : 1-833-256-2747

To learn more visit
www.AlynlamAssist.com

Please see Important Safety Information on [page 16](#)
and full [Prescribing Information](#).

Indication

ONPATTRO® (patisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

For additional information about ONPATTRO, please see the full [Prescribing Information](#).

Dosing guide⁹

ONPATTRO[®] (patisiran) is supplied as a 10 mg/5 mL solution in a single-dose vial.

ONPATTRO is administered via IV infusion once every 3 weeks.

Dosing is based on actual body weight. For patients weighing <100 kg, the recommended dose is 0.3 mg/kg. For patients weighing ≥100 kg, the recommended dose is 30 mg.

Proper preparation of ONPATTRO requires filtration to remove particulates. An additional vial of ONPATTRO may be required depending on the type of filter used and the amount of product that remains in the filter (hold-up volume).¹ **The dosing table below assumes that 1 mL of drug product remains in the filter when determining the number of vials needed,** based on the available manufacturer's information for the Pall PharmAssure[®] 0.45 micron 32 mm syringe filter with low protein binding Supor[®] membrane (Product ID HP4644).¹⁴

References: **1.** Ando Y, Coelho T, Berk JL, et al. *Orphanet J Rare Dis.* 2013;8:31. **2.** Coutinho P, Martins da Silva A, Lopes Lima JL, et al. *Excerpta Medica.* 1980:88-98. **3.** Conceição I, Gonzalez-Duarte A, Obici L, et al. *J Peripher Nerv Syst.* 2016;21(1):5-9. **4.** Ando Y, Nakamura M, Araki S. *Arch Neurol.* 2005;62(7):1057-1062. **5.** Coelho T, Merlini G, Bulawa CE, et al. *Neurol Ther.* 2016;5(1):1-25. **6.** Adams D, Coelho T, Obici L, et al. *Neurology.* 2015;85(8):675-682. **7.** Shin SC, Robinson-Papp J. *Mt Sinai J Med.* 2012;79(6):733-748. **8.** Ruberg FL, Grogan M, Hanna M, et al. *J Am Coll Cardiol.* 2019;73(22):2872-2891. **9.** ONPATTRO Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc. **10.** Gertz MA. *Am J Manag Care.* 2017;23(suppl 7):S107-S112. **11.** Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. *N Engl J Med.* 2018;379(1):11-21. **12.** Adams D, Suhr OB, Dyck PJ, et al. *BMC Neurol.* 2017;17(1):181. **13.** Vinik EJ, Vinik AI, Paulson JF, et al. *J Peripher Nerv Syst.* 2014;19:104-119. **14.** PharmAssure 32 mm syringe filters [manufacturing leaflet]. Port Washington, NY: Pall Corporation; 2010.

Please see Important Safety Information on [page 16](#) and full [Prescribing Information](#).

Dosing guide (cont'd)⁹

For patients weighing ≥ 100 kg, the recommended dose is 30 mg.

Note: The bolded numbers signify weights that may require an additional vial of ONPATTRO[®] (patisiran) due to drug product remaining in the filter.

Body Weight (kg)	mg	mL	Vials	Body Weight (kg)	mg	mL	Vials	Body Weight (kg)	mg	mL	Vials
25	7.5	3.75	1	50	15	7.5	2	75	22.5	11.25	3
26	7.8	3.9	1	51	15.3	7.65	2	76	22.8	11.4	3
27	8.1	4.05	2	52	15.6	7.8	2	77	23.1	11.55	3
28	8.4	4.2	2	53	15.9	7.95	2	78	23.4	11.7	3
29	8.7	4.35	2	54	16.2	8.1	2	79	23.7	11.85	3
30	9	4.5	2	55	16.5	8.25	2	80	24	12	3
31	9.3	4.65	2	56	16.8	8.4	2	81	24.3	12.15	3
32	9.6	4.8	2	57	17.1	8.55	2	82	24.6	12.3	3
33	9.9	4.95	2	58	17.4	8.7	2	83	24.9	12.45	3
34	10.2	5.1	2	59	17.7	8.85	2	84	25.2	12.6	3
35	10.5	5.25	2	60	18	9	2	85	25.5	12.75	3
36	10.8	5.4	2	61	18.3	9.15	3	86	25.8	12.9	3
37	11.1	5.55	2	62	18.6	9.3	3	87	26.1	13.05	3
38	11.4	5.7	2	63	18.9	9.45	3	88	26.4	13.2	3
39	11.7	5.85	2	64	19.2	9.6	3	89	26.7	13.35	3
40	12	6	2	65	19.5	9.75	3	90	27	13.5	3
41	12.3	6.15	2	66	19.8	9.9	3	91	27.3	13.65	3
42	12.6	6.3	2	67	20.1	10.05	3	92	27.6	13.8	3
43	12.9	6.45	2	68	20.4	10.2	3	93	27.9	13.95	3
44	13.2	6.6	2	69	20.7	10.35	3	94	28.2	14.1	4
45	13.5	6.75	2	70	21	10.5	3	95	28.5	14.25	4
46	13.8	6.9	2	71	21.3	10.65	3	96	28.8	14.4	4
47	14.1	7.05	2	72	21.6	10.8	3	97	29.1	14.55	4
48	14.4	7.2	2	73	21.9	10.95	3	98	29.4	14.7	4
49	14.7	7.35	2	74	22.2	11.1	3	99	29.7	14.85	4



ONPATTRO, Anylam Assist, and their associated logos are trademarks of Anylam Pharmaceuticals, Inc.
 © 2026 Anylam Pharmaceuticals, Inc. All rights reserved. TTR02-USA-00054-052018-V11

